이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AC Immune 관리

관리 기준 확인 3/4

AC Immune's CEO는 Andrea Pfeifer, Apr2003 에 임명되었습니다 의 임기는 21.17 년입니다. 총 연간 보상은 CHF 2.65M, 21.8% 로 구성됩니다. 21.8% 급여 및 78.2% 보너스(회사 주식 및 옵션 포함). 는 $ 9.85M 가치에 해당하는 회사 주식의 2.58% 직접 소유합니다. 9.85M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 6.2 년입니다.

주요 정보

Andrea Pfeifer

최고 경영자

CHF2.7m

총 보상

CEO 급여 비율	21.8%
CEO 임기	21.2yrs
CEO 소유권	2.6%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	6.2yrs

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

Recent updates

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

CEO 보상 분석

Andrea Pfeifer 의 보수는 AC Immune 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CHF55m
Dec 31 2023	CHF3m	CHF578k	-CHF54m
Sep 30 2023	n/a	n/a	-CHF68m
Jun 30 2023	n/a	n/a	-CHF67m
Mar 31 2023	n/a	n/a	-CHF69m
Dec 31 2022	CHF2m	CHF558k	-CHF71m
Sep 30 2022	n/a	n/a	-CHF73m
Jun 30 2022	n/a	n/a	-CHF76m
Mar 31 2022	n/a	n/a	-CHF75m
Dec 31 2021	CHF2m	CHF530k	-CHF73m
Sep 30 2021	n/a	n/a	-CHF71m
Jun 30 2021	n/a	n/a	-CHF74m
Mar 31 2021	n/a	n/a	-CHF71m
Dec 31 2020	CHF2m	CHF520k	-CHF62m
Sep 30 2020	n/a	n/a	-CHF62m
Jun 30 2020	n/a	n/a	-CHF25m
Mar 31 2020	n/a	n/a	-CHF26m
Dec 31 2019	CHF2m	CHF510k	CHF45m
Sep 30 2019	n/a	n/a	CHF50m
Jun 30 2019	n/a	n/a	CHF18m
Mar 31 2019	n/a	n/a	CHF24m
Dec 31 2018	CHF2m	CHF455k	-CHF51m
Sep 30 2018	n/a	n/a	-CHF32m
Jun 30 2018	n/a	n/a	-CHF27m
Mar 31 2018	n/a	n/a	-CHF29m
Dec 31 2017	CHF2m	CHF404k	-CHF26m

보상 대 시장: Andrea 의 총 보상 ($USD 3.00M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Andrea 의 보상이 증가했습니다.

CEO

Andrea Pfeifer (67 yo)

21.2yrs

테뉴어

CHF2,650,000

보상

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrea Pfeifer	Co-Founder	21.2yrs	CHF2.65m	2.58% CHF 9.9m
Christopher Roberts	CFO & VP of Finance	2.2yrs	데이터 없음	0.013% CHF 51.3k
Piergiorgio Donati	Chief Technical Operations Officer	5.3yrs	데이터 없음	0.026% CHF 99.8k
Jean-Fabien Monin	Chief Administrative Officer	8.9yrs	데이터 없음	0.33% CHF 1.3m
Howard Donovan	Chief HR Officer	2.2yrs	데이터 없음	0.021% CHF 81.9k
Nuno Mendonca	Chief Medical Officer	less than a year	데이터 없음	0.0088% CHF 33.5k
Madiha Derouazi	Chief Scientific Officer	less than a year	데이터 없음	0.0034% CHF 12.9k
Gary Waanders	Senior VP of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Alexandre Caratsch	General Counsel	no data	데이터 없음	데이터 없음
Julian Snow	VP of U.S. Finance & Corporate Development	2.2yrs	데이터 없음	데이터 없음
David Hickman	Head of AD - SME	14.4yrs	데이터 없음	데이터 없음
Joseph Wettstein	Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer	8.3yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: ACIU 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andrea Pfeifer	Co-Founder	8.1yrs	CHF2.65m	2.58% CHF 9.9m
Jean-Marie Lehn	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Claude Nicolau	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Douglas Williams	Independent Non-Executive Chairman	6.2yrs	CHF179.00k	0.041% CHF 158.4k
Alf E. Lindberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Detlev Riesner	Member of Scientific Advisory Board	no data	CHF5.00k	데이터 없음
Fred Van Leuven	Member of Scientific Advisory Board	no data	CHF105.00k	데이터 없음
I. Rosenberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
M. Monsigny	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
E. Lestringant	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Monika Butler	Independent Vice Chair	2.7yrs	CHF163.00k	0.0097% CHF 37.2k
Andreas Monsch	Head of Clinical Advisory Board	no data	데이터 없음	데이터 없음

6.2yrs

평균 재임 기간

74.5yo

평균 연령

경험이 풍부한 이사회: ACIU 의 이사회는 경험(평균 재직 기간 6.2 년)으로 간주됩니다.

AC Immune 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA, Annual General Meeting, Jun 20, 2024

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Co-Founder notifies of intention to sell stock

Recent updates

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Consensus forecasts updated

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

AC Immune SA, Annual General Meeting, Mar 31, 2021

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

New 90-day high: US$8.43

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway